

Supplementary Materials: Co-encapsulation of fisetin and cis-platin for glioma therapy: from formulation to cell evaluation

Morgane Renault-Mahieux, Victoire Vieillard, Johanne Seguin, Philippe Espeau, Dang Tri Le, René Lai-Kuen, Nathalie Mignet, Muriel Paul and Karine Andrieux




Figure S1. Results representative of different DSC experiments of liposomes with increasing ratio of cholesterol (from 0 to 13 wt%), which were carried out in duplicate; cholesterol ratios of 20 and 30% led to an undetectable main transition and thus data are not shown.




Figure S2. Shelf stability of fisetin-loaded liposomes F3 over 30 days of storage. Black shows results after size-exclusion chromatography purification and white shows results after filtration purification (n = 2).




Figure S3. Shelf stability of cisplatin-loaded liposomes F3 and F4 over 30 days of storage. Black shows results after size-exclusion chromatography purification and white shows results after dialysis purification (n = 2).